Clinical Trial Update: A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM) [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing Linvoseltamab to Daratumumab in high-risk smoldering multiple myeloma is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Smoldering Multiple Myeloma

Drugs mentioned

• Daratumumab (daratumumab)
• Linvoseltamab

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: High Risk Smoldering Multiple Myeloma (HR-SMM) | Phase 3 | Status: NOT_YET_RECRUITING